Allegro, Senju to develop integrin peptide therapy for vascular eye diseases

6th May 2013 (Last Updated May 6th, 2013 18:30)

Allegro Ophthalmics and Senju Pharmaceutical have signed a collaboration and license deal to develop and market integrin peptide therapy as a first in-class treatment for vascular eye diseases in Japan.

Allegro Ophthalmics and Senju Pharmaceutical have signed a collaboration and license deal to develop and market integrin peptide therapy as a first in-class treatment for vascular eye diseases in Japan.

The collaboration is focused on developing integrin peptide therapy, with the aim of improving the quality of life for patients across the world who continue to remain at risk of blindness from vascular eye diseases.

Allegro Ophthalmics chief operating officer Marc Kirshbaum said Senju is one of the leading ophthalmic pharmaceutical companies in Japan.

"In addition to validating the potential of integrin peptide therapy as an additional treatment option for millions of patients at risk of blindness, this partnership provides Allegro with the capital required to significantly progress its clinical program across multiple indications and phases in the United States," Kirshbaum said.

As per the terms of the deal, Senju will acquire the rights to co-develop and market Allegro's therapy in Japan as an intravitreal injection for vascular eye diseases, including wet age-related macular degeneration and diabetic macular edema.

Allegro is eligible for an upfront license fee, additional development and sales milestone fees, and a percentage royalty on net sales.

Senju Pharmaceutical executive vice president Shuhei Yoshida said; "We believe that Allegro's integrin peptide therapy shows great promise as a first-in-class treatment for wet AMD, DME and other vascular eye indications, and we are eager to begin the process for regulatory approval in Japan."

Summit Pharmaceuticals International, a subsidiary of Sumitomo, advised Allegro on the transaction.

Allegro completed enrolment in a Phase Ib/IIa study in wet AMD patients as stand-alone therapy, and initiated a Phase Ib/IIa trial in combination with anti-VEGF therapy, both of which are in addition to a previous Phase I study in end-stage DME patients.